Back

What’s coming next: zalunfiban for primary PCI in STEMI

14 March 2025 (17:20 - 17:30)
Organised by: Logo
Congress Presentation Part of: State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift? Pharmacotherapy ACVC Premium Access ESC Acute CardioVascular Care 2025 Association for Acute CardioVascular Care (ACVC)

About the speaker

Photo
Professor Uwe Zeymer

Foundation Institute for Heart Attack Research, Ludwigshafen (Germany)

6 More presentations in this session

Presentation thumbnail
How to approach periprocedural antithrombotic treatment
Professor I. Ahrens (Cologne, DE)
Slides
Presentation thumbnail
How to individualise antiplatelet therapy: from DAPT shortening to de-escalation
Professor P. Vranckx (Hasselt, BE)
Slides
Presentation thumbnail
How to adapt antithrombotic treatment in specific clinical scenarios
Associate Professor S. Leonardi (Pavia, IT)
Slides
Presentation thumbnail
Antiplatelet strategies in acute myocardial infarction cardiogenic shock (AMICS)
Doctor S. Gorgis (Detroit, US)
Slides
Presentation thumbnail
State-of-the-art antithrombotic treatment in acute coronary syndromes - discussion

Access the full session

Session thumbnail
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?
Video

The Event

Event poster

ESC Acute CardioVascular Care 2025

14 March 2025 17:20 CET
You may be interested in
thumbnail
Congress Presentation
The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction
18 March 2022
thumbnail
Congress Presentation
Primary PCI in a regional centre 7 years of change and improvement
21 March 2026
thumbnail
ESC Journals
Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry
19 October 2022
thumbnail
Congress Presentation
Efficacy and safety of upstream unfractionated heparin compared with downstream administration in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.
8 March 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources